Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Bristol-Myers Squibb Company

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb, with a price target of $55.00. Bans...

Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo

Jefferies analyst maintained a Buy rating on Bristol-Myers Squibb on December 4 and set a price target of $68.00. The company’s shares closed yeste...

Bristol-Myers Squibb (BMY) Gets a Buy from Jefferies

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), Bristol-Myers Squibb (BMY – Rese...

Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Bristol-Myers Squibb (BMY) and Johnson & Johnson (JNJ)

The share price has rallied over the past month.


Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues

British drugmaker AstraZeneca ($AZN), fresh off a record-high stock price, continues to draw interest from U.S. and European investors thanks to, a...

Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) announced price cuts across...

Novo Nordisk Stock (NVO) Jumps after Ozempic and Wegovy Prices Cut 71% under Medicare Plan

Scotiabank analyst Louise Chen maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $45.00. According to TipRanks, Chen...

Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank

In a report released today, from Jefferies maintained a Buy rating on Bristol-Myers Squibb, with a price target of $68.00. In addition to Jefferies...

Jefferies Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD – Research Report), Bristol-Myers...

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD), Bristol-Myers Squibb (BMY) and PACS Group Inc (PACS)

Jefferies analyst maintained a Buy rating on Bristol-Myers Squibb today and set a price target of $68.00. In addition to Jefferies, Bristol-Myers S...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acrivon Therapeutics, Inc. (ACRV – Research Report...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMY	$50.93	-0.55%	5.04M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMY	$50.93	-0.5%	5.04M
3
4
5
6

BMY

BMY

Compare Stocks

Start Your Comparison

Get Bristol-Myers Squibb Company Data in Excel

Get Bristol-Myers Squibb Company Data in Excel